Fredrik Celsing
- Hematology top 2%
- Multiple Myeloma Research and Treatments 7
- Erythropoietin and Anemia Treatment 4
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research 11
-
- Lymphoma Diagnosis and Treatment 8
- Immunology top 10%
- Immunodeficiency and Autoimmune Disorders 4
-
- Cell death mechanisms and regulation 5
-
- Muscle metabolism and nutrition 4
-
- Cardiovascular and exercise physiology 4
- Co-authors
- Eva BlomstrandEric A. NewsholmeAnders ÖsterborgMagnus BjörkholmJeanette LundinBjörn EkblomP. PihlstedtEva Kimby
- Partner nations
- SwedenUnited KingdomBelgium
In The Last Decade
Fredrik Celsing
44 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 110
- Hematology 563
- Genetics 505
- Pathology and Forensic Medicine 392
- Immunology 384
- Orthopedics and Sports Medicine 133
Countries citing papers authored by Fredrik Celsing
This map shows the geographic impact of Fredrik Celsing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fredrik Celsing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fredrik Celsing more than expected).
Fields of papers citing papers by Fredrik Celsing
This network shows the impact of papers produced by Fredrik Celsing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fredrik Celsing. The network helps show where Fredrik Celsing may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fredrik Celsing, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 36 | |
| 2 | 2012 | 42 | |
| 3 | 2011 | 5 | |
| 4 | 2007 | 47 | |
| 5 | 2004 | 66 | |
| 6 | 2003 | 33 | |
| 7 | 2003 | 8 | |
| 8 | 2003 | 33 | |
| 9 | 2002 | 13 | |
| 10 | 2002 | 19 | |
| 11 | Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). | 2001 | 4 |
| 12 | 2001 | 5 | |
| 13 | 2000 | 203 | |
| 14 | Thalidomide frequently induces good partial remission and best response ever in patients with advanced myeloma and prior high dose melphalan and autotransplant. | 1999 | 6 |
| 15 | 1998 | 9 | |
| 16 | 1998 | 8 | |
| 17 | 1997 | 32 | |
| 18 | 1994 | 4 | |
| 19 | 1990 | 14 | |
| 20 | 1988 | 15 |
About Fredrik Celsing
Fredrik Celsing is a scholar working on Hematology, Genetics, Complementary and alternative medicine, Pathology and Forensic Medicine and Rehabilitation, having authored 44 papers that have together received 1.8k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (8 papers), Multiple Myeloma Research and Treatments (7 papers), Cell death mechanisms and regulation (5 papers), Muscle metabolism and nutrition (4 papers), Erythropoietin and Anemia Treatment (4 papers), Cardiovascular and exercise physiology (4 papers) and Immunodeficiency and Autoimmune Disorders (4 papers). The work is most often cited by research in Hematology (563 citations), Genetics (505 citations), Pathology and Forensic Medicine (392 citations), Immunology (384 citations) and Orthopedics and Sports Medicine (133 citations). Fredrik Celsing has collaborated with scholars based in Sweden, United Kingdom and Belgium. Frequent co-authors include Eva Blomstrand, Eric A. Newsholme, Anders Österborg, Magnus Björkholm, Jeanette Lundin, Björn Ekblom, P. Pihlstedt, Eva Kimby, Magnus Adriansson and Claes Malm. Their work appears in journals such as Blood, British Journal of Haematology, Leukemia, Medical Oncology and European Journal of Applied Physiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.